Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 430

1.

Assessing the in vivo efficacy of biologic antiangiogenic therapies.

Wilson PM, LaBonte MJ, Lenz HJ.

Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Review.

PMID:
23053262
2.

The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.

Fakih M.

Expert Rev Anticancer Ther. 2013 Apr;13(4):427-38. doi: 10.1586/era.13.20. Epub 2013 Feb 22. Review.

PMID:
23432698
3.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
4.

Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.

Leite de Oliveira R, Hamm A, Mazzone M.

Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Review.

PMID:
21540050
5.

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

Teoh D, Secord AA.

Int J Gynecol Cancer. 2012 Mar;22(3):348-59. doi: 10.1097/IGC.0b013e31823c6efd. Review.

PMID:
22266932
6.

Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.

Chung C, Pherwani N.

Am J Health Syst Pharm. 2013 Nov 1;70(21):1887-96. doi: 10.2146/ajhp130143. Review.

PMID:
24128964
7.

Antiangiogenic therapy for high-grade gliomas.

Chamberlain MC, Raizer J.

CNS Neurol Disord Drug Targets. 2009 Jun;8(3):184-94. Review.

PMID:
19601816
8.

Challenges for patient selection with VEGF inhibitors.

Longo R, Gasparini G.

Cancer Chemother Pharmacol. 2007 Jul;60(2):151-70. Epub 2007 Mar 17. Review.

PMID:
17370072
9.

Radiolabeled small molecule inhibitors of VEGFR - recent advances.

Kniess T.

Curr Pharm Des. 2012;18(20):2867-74. Review.

PMID:
22571655
10.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
11.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
12.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
13.

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J.

Crit Rev Oncog. 2012;17(1):51-67. Review.

PMID:
22471664
14.

Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.

Quesada AR, Medina MA, Alba E.

Bioessays. 2007 Nov;29(11):1159-68. Review.

PMID:
17935210
15.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

PMID:
20167562
16.

Targeted therapy for metastatic colorectal cancer: role of aflibercept.

Mitchell EP.

Clin Colorectal Cancer. 2013 Jun;12(2):73-85. doi: 10.1016/j.clcc.2012.08.001. Epub 2012 Oct 24. Review.

PMID:
23102896
17.

Antiangiogenic therapies: is VEGF-A inhibition alone enough?

Gordon MS.

Expert Rev Anticancer Ther. 2011 Mar;11(3):485-96. doi: 10.1586/era.11.5.

PMID:
21417860
18.

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.

Miletic H, Niclou SP, Johansson M, Bjerkvig R.

Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444 . Review.

PMID:
19335067
19.

The possible role of chemotherapy in antiangiogenic drug resistance.

Bocci G, Loupakis F.

Med Hypotheses. 2012 May;78(5):646-8. doi: 10.1016/j.mehy.2012.02.001. Epub 2012 Feb 25.

PMID:
22365648
20.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
Items per page

Supplemental Content

Write to the Help Desk